Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Niraparib Tosylate

FDA-approved product (capsule, oral), marketed as Zejula.

Registered studies
7
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Niraparib Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Fallopian Tube Carcinoma
  • Neoplasm
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Peritoneal neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Poly (adp-ribose) polymerase (parp) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Niraparib Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Niraparib Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)

    NCT06594679 · start 2024-09-26

    Registered record
    Registry ID
    NCT06594679
    Conditions
    Ovarian Cancer
    Interventions
    Niraparib Tosylate Monohydrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-09-26
    Completion
    2027-09-18
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionNiraparib Tosylate Monohydrate
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

    NCT05689021 · start 2024-03-05

    Registered record
    Registry ID
    NCT05689021
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone Acetate/Niraparib; Biospecimen Collection; Bone Scan; Computed Tomography; Magnetic Resonance Imaging; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2024-03-05
    Completion
    2026-07-02
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionAbiraterone Acetate/Niraparib; Biospecimen Collection; Bone Scan; Computed Tomography +2 more
    PhasePhase 2
    Registry statusTerminated

  • Niraparib for the Treatment of Leiomyosarcoma

    NCT05174455 · start 2023-12-01

    Registered record
    Registry ID
    NCT05174455
    Conditions
    Locally Advanced Leiomyosarcoma; Metastatic Leiomyosarcoma; Stage III Retroperitoneal Sarcoma AJCC v8; Stage IIIA Retroperitoneal Sarcoma AJCC v8; Stage IIIB Retroperitoneal Sarcoma AJCC v8; Stage IV Retroperitoneal Sarcoma AJCC v8; Unresectable Leiomyosarcoma
    Interventions
    Niraparib Tosylate Monohydrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-12-01
    Completion
    2025-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Leiomyosarcoma; Metastatic Leiomyosarcoma; Stage III Retroperitoneal Sarcoma AJCC v8; Stage IIIA Retroperitoneal Sarcoma AJCC v8 +3 more
    InterventionNiraparib Tosylate Monohydrate
    PhasePhase 2
    Registry statusWithdrawn

  • Niraparib Efficacy in Patient With Unresectable Mesothelioma

    NCT05455424 · start 2022-07-11

    Registered record
    Registry ID
    NCT05455424
    Conditions
    Mesothelioma, Malignant
    Interventions
    Niraparib Oral Product; Active Symptom Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-11
    Completion
    2025-01-31
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMesothelioma, Malignant
    InterventionNiraparib Oral Product; Active Symptom Control
    PhasePhase 2
    Registry statusCompleted

  • Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

    NCT04481113 · start 2021-06-07

    Registered record
    Registry ID
    NCT04481113
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; HER2 Negative Breast Adenocarcinoma; Hormone Receptor Positive Breast Adenocarcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Unilateral Breast Carcinoma
    Interventions
    Abemaciclib; Niraparib Tosylate Monohydrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-07
    Completion
    2025-06-20
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8 +16 more
    InterventionAbemaciclib; Niraparib Tosylate Monohydrate
    PhasePhase 1
    Registry statusCompleted

  • Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

    NCT04030559 · start 2020-02-25

    Registered record
    Registry ID
    NCT04030559
    Conditions
    ATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CDK12 Gene Mutation; CHEK1 Gene Mutation; CHEK2 Gene Mutation; DNA Damage Response Gene Mutation; DNA Repair Gene Mutation; FANCA Gene Mutation; FANCD2 Gene Mutation; FANCL Gene Mutation; GEN1 Gene Mutation; NBN Gene Mutation; Prostate Carcinoma; RAD51 Gene Mutation; RAD51C Gene Mutation
    Interventions
    Niraparib; Niraparib Tosylate Monohydrate; Radical Prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-02-25
    Completion
    2025-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation +13 more
    InterventionNiraparib; Niraparib Tosylate Monohydrate; Radical Prostatectomy
    PhasePhase 2
    Registry statusTerminated

  • Niraparib/TTFields in GBM

    NCT04221503 · start 2019-12-30

    Registered record
    Registry ID
    NCT04221503
    Conditions
    Glioblastoma; Recurrent Glioblastoma; GBM
    Interventions
    Niraparib; Optune; Planned surgical resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-12-30
    Completion
    2026-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Recurrent Glioblastoma; GBM
    InterventionNiraparib; Optune; Planned surgical resection
    PhasePhase 2
    Registry statusActive not recruiting